ADMA Biologics Inc (ADMA) - Net Assets
Based on the latest financial reports, ADMA Biologics Inc (ADMA) has net assets worth $390.32 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($665.18 Million) and total liabilities ($274.86 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check ADMA Biologics Inc (ADMA) tangible equity ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $390.32 Million |
| % of Total Assets | 58.68% |
| Annual Growth Rate | N/A |
| 5-Year Change | 238.11% |
| 10-Year Change | N/A |
| Growth Volatility | 90534.86 |
ADMA Biologics Inc - Net Assets Trend (2006–2025)
This chart illustrates how ADMA Biologics Inc's net assets have evolved over time, based on quarterly financial data. See ADMA Biologics Inc (ADMA) liquidity interval to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for ADMA Biologics Inc (2006–2025)
The table below shows the annual net assets of ADMA Biologics Inc from 2006 to 2025. For live valuation and market cap data, see ADMA market cap overview.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $477.32 Million | +36.76% |
| 2024-12-31 | $349.02 Million | +158.14% |
| 2023-12-31 | $135.21 Million | -11.03% |
| 2022-12-31 | $151.97 Million | +7.65% |
| 2021-12-31 | $141.17 Million | +59.97% |
| 2020-12-31 | $88.25 Million | +236.92% |
| 2019-12-31 | $26.19 Million | +32.49% |
| 2018-12-31 | $19.77 Million | -50.98% |
| 2017-12-31 | $40.33 Million | +1004.88% |
| 2016-12-31 | $-4.46 Million | -642.92% |
| 2015-12-31 | $820.97K | -86.34% |
| 2014-12-31 | $6.01 Million | -72.15% |
| 2013-12-31 | $21.57 Million | +128.93% |
| 2012-12-31 | $9.42 Million | +339739.38% |
| 2011-12-31 | $2.77K | +901.45% |
| 2010-12-31 | $-346.00 | -- |
| 2009-12-31 | $0.00 | -- |
| 2008-12-31 | $0.00 | -- |
| 2007-12-31 | $0.00 | -- |
| 2006-12-31 | $0.00 | -- |
Equity Component Analysis
This analysis shows how different components contribute to ADMA Biologics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 16165300000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $24.00K | 0.01% |
| Other Components | $638.95 Million | 133.86% |
| Total Equity | $477.32 Million | 100.00% |
ADMA Biologics Inc Competitors by Market Cap
The table below lists competitors of ADMA Biologics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Newell Rubbermaid Inc.
NASDAQ:NWL
|
$1.90 Billion |
|
Jiangsu New Energy Development Co Ltd
SHG:603693
|
$1.90 Billion |
|
Charter Hall Long Wale REIT
AU:CLW
|
$1.90 Billion |
|
Citic Offshore Helicopter Co Ltd
SHE:000099
|
$1.90 Billion |
|
TPV Technology Co Ltd
SHE:000727
|
$1.90 Billion |
|
Sichuan Anning Iron and Titanium Co
SHE:002978
|
$1.90 Billion |
|
Shanghai Bailian Group Co Ltd A
SHG:600827
|
$1.90 Billion |
|
Nanjing Gaoke Co Ltd
SHG:600064
|
$1.90 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in ADMA Biologics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 349,018,000 to 477,320,000, a change of 128,302,000 (36.8%).
- Net income of 146,930,000 contributed positively to equity growth.
- Share repurchases of 31,940,000 reduced equity.
- Other factors increased equity by 13,312,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $146.93 Million | +30.78% |
| Share Repurchases | $31.94 Million | -6.69% |
| Other Changes | $13.31 Million | +2.79% |
| Total Change | $- | 36.76% |
Book Value vs Market Value Analysis
This analysis compares ADMA Biologics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 4.40x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2006-12-31 | $0.00 | $8.58 | x |
| 2007-12-31 | $0.00 | $8.58 | x |
| 2008-12-31 | $-0.01 | $8.58 | x |
| 2009-12-31 | $0.00 | $8.58 | x |
| 2010-12-31 | $0.00 | $8.58 | x |
| 2011-12-31 | $0.00 | $8.58 | x |
| 2012-12-31 | $1.79 | $8.58 | x |
| 2013-12-31 | $3.30 | $8.58 | x |
| 2014-12-31 | $0.65 | $8.58 | x |
| 2015-12-31 | $0.08 | $8.58 | x |
| 2016-12-31 | $-0.37 | $8.58 | x |
| 2017-12-31 | $1.76 | $8.58 | x |
| 2018-12-31 | $0.44 | $8.58 | x |
| 2019-12-31 | $0.48 | $8.58 | x |
| 2020-12-31 | $1.02 | $8.58 | x |
| 2021-12-31 | $1.01 | $8.58 | x |
| 2022-12-31 | $0.77 | $8.58 | x |
| 2023-12-31 | $0.60 | $8.58 | x |
| 2024-12-31 | $1.43 | $8.58 | x |
| 2025-12-31 | $1.95 | $8.58 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently ADMA Biologics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 30.78%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 28.80%
- • Asset Turnover: 0.82x
- • Equity Multiplier: 1.31x
- Recent ROE (30.78%) is above the historical average (-247.96%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2006 | 0.00% | 0.00% | 0.00x | 0.00x | $-29.69 Million |
| 2007 | -648.19% | 0.00% | 0.00x | 3.20x | $-30.14 Million |
| 2008 | 0.00% | 0.00% | 0.00x | 0.00x | $-23.56 Million |
| 2009 | 0.00% | 0.00% | 0.00x | 0.00x | $-19.73 Million |
| 2010 | 0.00% | 0.00% | 0.00x | 0.00x | $-20.49K |
| 2011 | -954.20% | 0.00% | 0.00x | 2.91x | $-26.74K |
| 2012 | -77.48% | -653.00% | 0.07x | 1.65x | $-8.24 Million |
| 2013 | -71.97% | -506.17% | 0.10x | 1.48x | $-17.68 Million |
| 2014 | -279.82% | -284.22% | 0.22x | 4.53x | $-17.41 Million |
| 2015 | -2188.85% | -250.36% | 0.30x | 28.89x | $-18.05 Million |
| 2016 | 0.00% | -183.05% | 0.45x | 0.00x | $-19.07 Million |
| 2017 | -108.49% | -192.26% | 0.21x | 2.68x | $-47.79 Million |
| 2018 | -332.53% | -387.06% | 0.19x | 4.50x | $-67.72 Million |
| 2019 | -184.32% | -164.50% | 0.23x | 4.85x | $-50.90 Million |
| 2020 | -85.83% | -179.41% | 0.20x | 2.35x | $-84.57 Million |
| 2021 | -50.75% | -88.52% | 0.29x | 1.96x | $-85.77 Million |
| 2022 | -43.37% | -42.77% | 0.44x | 2.29x | $-81.10 Million |
| 2023 | -20.89% | -10.94% | 0.78x | 2.43x | $-41.76 Million |
| 2024 | 56.64% | 46.35% | 0.87x | 1.40x | $162.77 Million |
| 2025 | 30.78% | 28.80% | 0.82x | 1.31x | $99.20 Million |
Industry Comparison
This section compares ADMA Biologics Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $296,451,843
- Average return on equity (ROE) among peers: -36.17%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| ADMA Biologics Inc (ADMA) | $390.32 Million | 0.00% | 0.70x | $1.90 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $81.00 Million |
| Abcellera Biologics Inc (ABCL) | $1.15 Billion | -12.70% | 0.29x | $1.55 Billion |
| Abeona Therapeutics Inc (ABEO) | $-17.08 Million | 0.00% | 0.00x | $321.39 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $-18.59 Million | 0.00% | 0.00x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $-75.73 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $1.01 Billion |
| Arbutus Biopharma Corp (ABUS) | $97.37 Million | -71.81% | 0.35x | $831.63 Million |
| ABVC Biopharma Inc (ABVC) | $2.46 Million | -172.46% | 1.68x | $33.54 Million |
| Abivax SA American Depositary Shares (ABVX) | $455.01 Million | -73.87% | 0.28x | $7.77 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $1.23 Billion | 31.86% | 0.27x | $3.59 Billion |
About ADMA Biologics Inc
ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company operates through ADMA BioManufacturing and Plasma Collection Centers segments. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indic… Read more